SummerStreet Research Partners Reiterates Buy Rating of Northwest Biotherapeutics, Inc.

Business & Professional Services

Share Tweet

SummerStreet Research Partners Reiterates Buy Rating of Northwest Biotherapeutics, Inc.

New York, NY / June 4, 2014 / Market Exclusive announces that SummerStreet Research Partners has reiterated a BUY rating and year end 2014 price target or $15.10 on Northwest Biotherapeutics, Inc. (NASDAQ: NWBO).

According to the SummerStreet Research report "NWBO has the potential to significantly improve the treatment of newly diagnosed GBM and other solid tumor cancers. NWBO has developed a platform technology, DCVax, that produces personalized immune therapy. NWBO has two product candidates for all solid tumors and a third product for prostate cancer."

NWBO is a biotechnology company developing immunotherapy products to treat cancers. The company has a broad platform technology with DCVax dendritic cell-based vaccines. The therapeutic vaccines utilize patients' own cells to destroy cancer cells with better specificity and less toxicity than traditional chemotherapies. The lead program is a 312- patient phase III trial in newly diagnosed GBM, the most aggressive and lethal form of brain cancer. The second product candidate is DCVax Direct, which has begun phase I/II trials at MD Anderson for all inoperable solid tumors. In addition, the FDA has approved a 612-patient phase III trial of DCVax for prostate cancer.

About Market Exclusive

Market Exclusive is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.


The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Market Exclusive